Comparison between efficacy of triamcinolone acetonide and bevacizumab in a case with type 2A idiopathic parafoveal telangiectasia Tip 2 İdiopatik parafoveal telenjektazili bir olguda bevacizumab ile triamsinolon asetonidin karflşılaflştırılması

Toklu Y., Raza S., Anayol M. A., Özkan B., Altintaş A. K., ŞİMŞEK Ş.

Turk Oftalmoloiji Dergisi, cilt.41, sa.1, ss.6-9, 2011 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.4274/tjo.41.02
  • Dergi Adı: Turk Oftalmoloiji Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.6-9
  • Anahtar Kelimeler: Type 2A idiopathic parafoveal telangiectasia, triamcinolone acetonide, bevacizumab
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To compare the efficacy of intravitreal triamcinolone acetonide and bevacizumab in the treatment of a case of type 2A idiopathic parafoveal telangiectasia (IPT). Material and Method: A 55-year-old man with complaint of decreased vision in both eyes was diagnosed as type 2A IPT after a complete ophthalmological examination, fundus fluorescein angiography (FA) and optical coherence tomography (OCT). We injected intravitreally 4 mg /0.1 cc of triamcinolone acetonide into the right eye and 24 hours later 1.25 mg /0.05 cc of bevacizumab into the left eye. The patient was evaluated on the first day, first week, first month, and the third month with FA and OCT. Results: Before treatment, best-corrected visual acuity (BCVA) was 5/100 in the right eye and 5/10 in the left eye. At the first-week post-treatment visit, BCVA improved to 5/10 in the right eye and 10/10 in the left eye. On FA, edema in the temporal foveal area was detected in both eyes. This macular edema began to decrease at the first-week visit. Visual acuity was the same on the first- and third-month visits. The FA findings also remained the same. During this 3-month follow-up period, the patient did not need any other additional treatment. Discussion: Intravitreal injections of triamcinolone acetonide and bevacizumab are optional modalities in the treatment of type 2 IPT. The efficacy and permanence of influence-duration of action of triamcinolone acetonide and bevacizumab were similar in our case.